A single centre, proof-of-concept clinical study for SM-88 in advanced metastatic cancer patients
Phase of Trial: Phase I
Latest Information Update: 31 Jan 2017
At a glance
- Drugs SM 88 (Primary)
- Indications Cancer
- Focus First in man; Proof of concept; Therapeutic Use
- Sponsors Tyme Technologies
- 31 Jan 2017 Results published in a Tyme Technologies media release.
- 28 Mar 2015 New trial record
- 19 Mar 2015 According to a Tyme technology media release, it is anticipated that IND will be submitted to the FDA by the second quarter of 2015.